Caribou aces its first round of human data in search of an off-the-shelf CAR-T breakthrough
Caribou Biosciences just flipped its first card on human data for its lead off-the-shelf anti-CD19 CAR-T, and it’s an ace.
The biotech reported out on a tiny group of patients — just five treatment-resistant individuals suffering from B cell non-Hodgkin’s lymphoma in this first round — and came up with a 100% overall response rate with an 80% complete response rate.
Those headline numbers quickly registered as a rare win these days in the bleak biotech sector, as Caribou’s share price $CRBU surged 25%.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,600+ biopharma pros reading Endpoints daily — and it's free.